BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 19514075)

  • 1. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
    Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
    Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
    Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
    Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.
    Spiegel J; Hellwig D; Möllers MO; Behnke S; Jost W; Fassbender K; Samnick S; Dillmann U; Becker G; Kirsch CM
    Brain; 2006 May; 129(Pt 5):1188-93. PubMed ID: 16513685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease.
    Li DH; Zhang LY; Hu YY; Jiang XF; Zhou HY; Yang Q; Kang WY; Liu J; Chen SD
    Parkinsonism Relat Disord; 2015 Aug; 21(8):923-8. PubMed ID: 26066091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substantia nigra echogenicity is correlated with nigrostriatal impairment in Machado-Joseph disease.
    Pedroso JL; Bor-Seng-Shu E; Felício AC; Braga-Neto P; Hoexter MQ; Teixeira MJ; Bressan RA; Barsottini OG
    Parkinsonism Relat Disord; 2013 Aug; 19(8):742-5. PubMed ID: 23680416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
    Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
    Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
    Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders.
    Walter U; Hoeppner J; Prudente-Morrissey L; Horowski S; Herpertz SC; Benecke R
    Brain; 2007 Jul; 130(Pt 7):1799-807. PubMed ID: 17329323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.
    Alvarez-Fischer D; Blessmann G; Trosowski C; Béhé M; Schurrat T; Hartmann A; Behr TM; Oertel WH; Höglinger GU; Höffken H
    Neuroimage; 2007 Oct; 38(1):5-12. PubMed ID: 17716921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease.
    Lobsien E; Schreiner S; Plotkin M; Kupsch A; Schreiber SJ; Doepp F
    Mov Disord; 2012 Mar; 27(3):450-3. PubMed ID: 22237792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease.
    Walter U; Wittstock M; Benecke R; Dressler D
    J Neural Transm (Vienna); 2002 Feb; 109(2):191-6. PubMed ID: 12075859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.
    Booij J; Berendse HW
    J Neurol Sci; 2011 Nov; 310(1-2):40-3. PubMed ID: 21840542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
    Cordes M; Poewe W
    Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.